EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.932
https://www.valueinhealthjournal.com/article/S1098-3015(23)04062-7/fulltext
Title :
EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04062-7&doi=10.1016/j.jval.2023.09.932
First page :
Section Title :
Open access? :
No
Section Order :
10426